Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cystic Fibrosis Lung Immunity: The Role of the Macrophage
Emanuela M. Bruscia, Tracey L. Bonfield
Journal of Innate Immunity (2016) Vol. 8, Iss. 6, pp. 550-563
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

Inflammation in cystic fibrosis: An update
Erica A. Roesch, David P. Nichols, James F. Chmiel
Pediatric Pulmonology (2018) Vol. 53, Iss. S3
Open Access | Times Cited: 211
Neutrophil Elastase and Chronic Lung Disease
Judith A. Voynow, Meagan Shinbashi
Biomolecules (2021) Vol. 11, Iss. 8, pp. 1065-1065
Open Access | Times Cited: 140
Innate Immunity of the Lung: From Basic Mechanisms to Translational Medicine
Dominik Hartl, Rabindra Tirouvanziam, Julie Laval, et al.
Journal of Innate Immunity (2018) Vol. 10, Iss. 5-6, pp. 487-501
Open Access | Times Cited: 118
Animal Models in the Pathophysiology of Cystic Fibrosis
Anna Semaniakou, Roger P. Croll, Valérie Chappe
Frontiers in Pharmacology (2019) Vol. 9
Open Access | Times Cited: 99
Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation
Meraj A. Khan, Zubair Ali, Neil Sweezey, et al.
Genes (2019) Vol. 10, Iss. 3, pp. 183-183
Open Access | Times Cited: 95
Mechanistic insight into the function of the microbiome in lung diseases
Niki Ubags, Benjamin J. Marsland
European Respiratory Journal (2017) Vol. 50, Iss. 3, pp. 1602467-1602467
Open Access | Times Cited: 91
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function
Shuzhong Zhang, Chandra L. Shrestha, Benjamin T. Kopp
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 89
CFTR Protein: Not Just a Chloride Channel?
L. Hanssens, Jean Duchateau, Georges Casimir
Cells (2021) Vol. 10, Iss. 11, pp. 2844-2844
Open Access | Times Cited: 78
Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis
Jonas C. Schupp, Sara Khanal, José L. Gómez, et al.
American Journal of Respiratory and Critical Care Medicine (2020) Vol. 202, Iss. 10, pp. 1419-1429
Open Access | Times Cited: 70
ScRNA-seq expression ofIFI27andAPOC2identifies four alveolar macrophage superclusters in healthy BALF
Xin Li, Fred Kolling, Daniel Aridgides, et al.
Life Science Alliance (2022) Vol. 5, Iss. 11, pp. e202201458-e202201458
Open Access | Times Cited: 39
Macrophage Dysfunction in Respiratory Disease
Kylie Belchamber, Louise Donnelly
Results and problems in cell differentiation (2017), pp. 299-313
Closed Access | Times Cited: 78
In Vitro and In Vivo Anti-Inflammatory Effects of Polyphyllin VII through Downregulating MAPK and NF-κB Pathways
Chao Zhang, Zesong Li, Xuejing Jia, et al.
Molecules (2019) Vol. 24, Iss. 5, pp. 875-875
Open Access | Times Cited: 74
Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa
Roxanna Barnaby, Katja Koeppen, Amanda Nymon, et al.
AJP Lung Cellular and Molecular Physiology (2017) Vol. 314, Iss. 3, pp. L432-L438
Open Access | Times Cited: 66
Pseudomonas aeruginosa LasB Subverts Alveolar Macrophage Activity by Interfering With Bacterial Killing Through Downregulation of Innate Immune Defense, Reactive Oxygen Species Generation, and Complement Activation
Fabien Bastaert, Saadé Kheir, Vinciane Saint‐Criq, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 62
Treating Cystic Fibrosis with mRNA and CRISPR
Alejandro Da Silva Sanchez, Kalina Paunovska, Ana Cristian, et al.
Human Gene Therapy (2020) Vol. 31, Iss. 17-18, pp. 940-955
Open Access | Times Cited: 51
Cathepsins in Bacteria-Macrophage Interaction: Defenders or Victims of Circumstance?
Lidia Szulc‐Dąbrowska, Magdalena Bossowska-Nowicka, Justyna Struzik, et al.
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 50
Resolvin D1 and D2 reduce SARS‐CoV‐2‐induced inflammatory responses in cystic fibrosis macrophages
Antonio Recchiuti, Sara Patruno, Domenico Mattoscio, et al.
The FASEB Journal (2021) Vol. 35, Iss. 4
Open Access | Times Cited: 50
Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease
Claire Healy, Natalia Muñoz‐Wolf, Janné Strydom, et al.
Respiratory Research (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 50
CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
Francesca Saluzzo, Luca Riberi, Barbara Messore, et al.
Cells (2022) Vol. 11, Iss. 7, pp. 1243-1243
Open Access | Times Cited: 36
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor
Shuzhong Zhang, Chandra L. Shrestha, Frank Robledo‐Avila, et al.
European Respiratory Journal (2022) Vol. 61, Iss. 4, pp. 2102861-2102861
Open Access | Times Cited: 35
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
Lindsay J. Caverly, Sebastián A. Riquelme, Katherine B. Hisert
Clinics in Chest Medicine (2022) Vol. 43, Iss. 4, pp. 647-665
Open Access | Times Cited: 31
Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators
Carla M. P. Ribeiro, Matthew G. Higgs, Marianne S. Muhlebach, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 5010-5010
Open Access | Times Cited: 22
Aerosol pulmonary immune engineering
Emma R. Sudduth, Michael Trautmann-Rodriguez, Nicole Gill, et al.
Advanced Drug Delivery Reviews (2023) Vol. 199, pp. 114831-114831
Open Access | Times Cited: 18
SARS-CoV-2 (COVID-19) and cystic fibrosis
Bruce A. Stanton, Thomas H. Hampton, Alix Ashare
AJP Lung Cellular and Molecular Physiology (2020) Vol. 319, Iss. 3, pp. L408-L415
Open Access | Times Cited: 49
Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis
Antonio Recchiuti, Domenico Mattoscio, Elisa Isopi
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top